Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can increase the risk ...
The U.S. drugmaker spent nearly $2 billion in 2023 to acquire Versanis Bio's bimagrumab, which prevents the activity of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback